Active substanceArginine glutamateArginine glutamate
Similar drugsTo uncover
  • Glutargin
    pills inwards 
  • Glutargin
    pills inwards 
  • Glutargin
    solution d / infusion 
  • Glutargin
    concentrate d / infusion 
  • Glutargin alkocline
    pills inwards 
  • Glutargin alkocline
    powder inwards 
  • Dosage form: & nbsppills
    Composition:

    In 1 tablet:

    active ingredient: arginine glutamate (in terms of 100% substance) 0.75 g.

    Excipients: cellulose microcrystalline (MCC 101) 0.102 g, crospovidone 0.020 g, calcium stearate 0.008 g.

    Description:Tablets are white, biconvex, oblong with a risk.
    Pharmacotherapeutic group:Hepatoprotective agent
    ATX: & nbsp

    A.05.B.A   Preparations for the treatment of liver diseases

    Pharmacodynamics:

    The drug Glutargin is a compound of arginine and glutamic acid, which play an important role in providing biochemical processes of neutralizing and removing from the body a highly toxic metabolite of nitrogen metabolism - ammonia.Hypoammonemic effects of the drug are realized by activating the neutralization of ammonia in the ornithine cycle of urea synthesis, the binding of ammonia to non-toxic glutamine, as well as increasing the excretion of ammonia from the central nervous system and its excretion from the body. As a result, general toxic, including neurotoxic, effects of ammonia are reduced.

    The drug Glutargin has a hepatoprotective effect, possessing antioxidant, antihypoxic and membrane-stabilizing activity, positively influences the energy supply in hepatocytes.

    When alcohol intoxication drug Glutargin stimulates the utilization of alcohol in the monooxygenase system of the liver, prevents the inhibition of the key enzyme for the utilization of ethanol - alcohol dehydrogenase; accelerates inactivation and elimination of toxic products of ethanol metabolism as a result of increased formation and oxidation of succinic acid; reduces the inhibitory effect of alcohol on the CNS due to the neurotransmitter properties of the excitatory glutamic acid.

    In the pathology of pregnancy due to endothelium-protective action, the drug Glutargin reduces the impaired permeability andthrombore resistance of blood vessels, prevents hypercoagulation, reduces the sensitivity of vessels to vasoconstrictor agents (endothelium, angiotensin, thromboxane), which causes generalized vasospasm. Arginine after preliminary biotransformation into nitric oxide has a vasodilating effect, positively affects the blood coagulation and the functional properties of the circulating elements of the blood. As a result of vasodilator and antihypoxic effects of the drug Glutargin, fetoplacental hemodynamics improves, intrauterine hypoxia of the fetus decreases. In the pathology of pregnancy, the drug also exhibits antitoxic and hepatoprotective activity, acts as a nonspecific metabolic regulator of metabolic processes. Due to these properties of the drug Glutargin during pregnancy, the level of immune complexes circulating in the blood decreases, the severity of the syndrome of "metabolic" intoxication and immunotoxicosis decreases, the compensatory-adaptive reactions of the organism increase. The drug Glutargin has no embryotoxic, gonadotoxic, mutagenic and teratogenic effects,does not cause allergic and immunotoxic reactions.

    Pharmacokinetics:Not studied.
    Indications:

    Applied in the complex therapy of acute and chronic hepatitis of various etiologies, poisoning with hepatotropic poisons (pale toadstool, chemical and medicinal substances), liver cirrhosis, leptospirosis; hepatic encephalopathy, precoma and coma accompanied by hyperammonemia. Prevention of alcohol intoxication; the state of acute alcohol poisoning of mild and moderate degree, hangover syndrome, postintoxication disorders caused by alcohol intake.

    Complications in the III trimester of pregnancy: late gestosis and fetoplacental insufficiency.

    Contraindications:

    - hypersensitivity to the components of the drug

    - children under 18 years of age

    -I and II trimesters of pregnancy

    - the period of breastfeeding

    Carefully:

    feverish condition

    - increased excitability

    - severe violations of the filtration (nitrogen excretory) function of the kidneys (creatinine clearance less than 30 ml / min)

    Pregnancy and lactation:

    The safety of the clinical use of the drug in the first and second trimesters of pregnancy and during breastfeeding has not been investigated.If it is necessary to use the drug during breastfeeding, breast-feeding should be stopped.

    Dosing and Administration:

    The drug is given to adults by mouth 1 tablet 3 times a day for 14 days, regardless of food intake. If necessary, a single dose of the drug can be increased to 3 tablets, the course of treatment - up to 21 days.

    To treat alcohol poisoning appoint 1-1.5 tablets 4 times a day at intervals of 1-2.5 h, in the next 2 - 3 days - 1 tablet 2 times a day. If alcohol poisoning is severe, after a course of intravenous administration of Glutargin, appoint 1 tablet 2 times a day for 20 days.

    To prevent alcohol intoxication appoint 2.5 tablets for 60-120 minutes before drinking alcohol.

    With the pathology of pregnancy in the III trimester, 1 tablet is prescribed 3 times a day for 14 days. The maximum single dose is 0.75 g, the maximum daily 2.25 g.

    Side effects:Seldom can there be a feeling of mild discomfort in the epigastric region and nausea immediately after using the drug, which pass on their own.
    Overdose:

    Symptoms: nausea, vomiting, pain in the chest, discomfort in the epigastric region, insomnia transient short-term decrease in arterial pressure, atrioventricular blockade, allergic reactions.

    Treatment: symptomatic, if necessary, taking antihistamines, in severe cases - intravenous glucocorticosteroids.

    Interaction:

    Care should be taken when Glutargin is combined with the following medicines:

    Aminophylline increases the concentration of endogenous insulin in the blood under the influence of Glutargin. Glutargin can enhance the effect of antiplatelet agents (dipyridamole , etc.), prevents and weakens neurotoxic phenomena that can occur with isoniazid therapy, weakens the effect of vinblastine.

    Special instructions:When appointing patients with impaired functions of the endocrine glands, it should be taken into account that the drug may slightly increase the secretion of insulin and growth hormone, which does not require correction of medical therapy in patients with diabetes mellitus and / or acromegaly.
    Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to drive vehicles.
    Form release / dosage:Tablets 0.75 g.
    Packaging:For 10 tablets in a planar cell package. For 3 or 5 contour packs of 10 tablets together with instructions for medical use in a pack of cardboard.
    Storage conditions:Store in a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:

    2 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000074
    Date of registration:10.12.2010 / 13.01.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:HEALTH PHARMACEUTICAL COMPANY, LTD. HEALTH PHARMACEUTICAL COMPANY, LTD. Ukraine
    Manufacturer: & nbsp
    Information update date: & nbsp01.05.2017
    Illustrated instructions
      Instructions
      Up